Newly identified markers may predict who will respond to breast cancer prevention therapy

(American Association for Cancer Research) Genetic variations, known as single nucleotide polymorphisms, in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news